| Bioactivity | Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1]. |
| Target | CEA. |
| In Vivo | Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo[1]. Animal Model: |
| Name | Labetuzumab |
| CAS | 219649-07-7 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther. 2004 Dec;3(12):1559-64. |